Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial

Objectives/Hypothesis We compared the effectiveness of venlafaxine and propranolol for the prophylaxis of vestibular migraine (VM). Study Design Prospective, randomized, controlled clinical trial. Methods Sixty‐four subjects with definite VM were enrolled. The subjects were randomly assigned to rece...

Full description

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2016-01, Vol.126 (1), p.169-174
Main Authors: Salviz, Mehti, Yuce, Turgut, Acar, Hurtan, Karatas, Abdullah, Acikalin, R. Murat
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antidepressive Agents, Second-Generation - therapeutic use
Anxiety
depression
Depression - drug therapy
dizziness handicap inventory
Female
Humans
Male
Middle Aged
migraine
Migraine Disorders - prevention & control
Migraine Disorders - psychology
prophylaxis
Propranolol - therapeutic use
Prospective Studies
Vasodilator Agents - therapeutic use
Venlafaxine Hydrochloride - therapeutic use
vertigo
Vestibular Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives/Hypothesis We compared the effectiveness of venlafaxine and propranolol for the prophylaxis of vestibular migraine (VM). Study Design Prospective, randomized, controlled clinical trial. Methods Sixty‐four subjects with definite VM were enrolled. The subjects were randomly assigned to receive propranolol (group P, n = 33) or venlafaxine (group V, n = 31) for VM prophylaxis. Dizziness Handicap Inventory (DHI) scores, the Vertigo Severity Score (VSS), and the number of vertiginous attacks were recorded before and 4 months after treatment. The Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were also recorded to monitor the resolution of psychiatric symptoms. Results At 4 months after treatment, the DHI total score decreased from 55.8 ± 2.7 to 31.3 ± 3.7 and from 50.9 ± 2.5 to 19.9 ± 2.9 (P 
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.25445